The detection of HER2-positive metastases in case of HER2-negative primary cancer using [89Zr]Zr-trastuzumab was addressed by Ulaner et al. in two related, consecutive clinical studies including a total of 20 patients [181,183]. This evidence concerns the gene ERBB2 and cancer.